Fig. 2. Impact of remission status at the timepoint of allo-SCT and therapy line on outcome: patients who reached MRD-negative¹ CR1 (n = 69) vs. those with MRD-positive CR1 (n = 33) vs. those with primary refractory disease (n = 14) vs. patients transplanted in case of relapse who reached MRD-negative¹ CR2 (n = 18) vs. those with MRD-positive CR2 (n = 5) vs. those with relapsed refractory disease (n = 41).

a Kaplan–Meier estimates for OS, b Kaplan–Meier estimates for PFS, c cumulative incidence of relapse, d cumulative incidence of NRM. Allo-SCT allogeneic transplantation, OS overall survival, PFS progression free survival, RR relapse rate, NRM non-relapse-related mortality; yyear, CR complete remission, MRD minimal residual disease, neg negative, pos positive. ¹Analysis of Ig-/TR-gene rearrangements via RQ-PCR and via surface marker analysis by flow cytometry.